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Abstract
Purpose The design, conduct and completion of randomized trials for curative prostate cancer (PCa) treatments are chal-
lenging. To evaluate the effect of robot-assisted radical prostatectomy (RARP) versus focal irreversible electroporation (IRE) 
on patient-reported quality of life (QoL) and early oncological control using propensity-scored matching.
Methods Patients with T1c–cT2b significant PCa (high-volume ISUP 1 or any 2/3) who received unifocal IRE were pair-
matched to patients who received nerve-sparing RARP. Patient-reported outcomes were prospectively assessed using the 
Expanded Prostate Cancer Index Composite (EPIC), AUA symptom score and Short Form of Health Survey (SF-12) physical 
and mental components. Oncological failure was defined as biochemical recurrence (RARP) or positive follow-up biopsies 
(IRE). Generalized mixed-effect models were used to compare IRE and RARP.
Results 50 IRE patients were matched to 50 RARP patients by propensity score. IRE was significantly superior to RARP 
in preserving pad-free continence (UC) and erections sufficient for intercourse (ESI). The absolute differences were 44, 21, 
13, 14% for UC and 32, 46, 27, 22% for ESI at 1.5, 3, 6, and 12 months, respectively. The EPIC summary scores showed 
no statistically significant differences. Urinary symptoms were reduced for IRE and RARP patients at 12 months, although 
IRE patient initially had more complaints. IRE patients experienced more early oncological failure than RARP patients.
Conclusions These data demonstrated the superior preservation of UC and ESI with IRE compared to RARP up to 12 months 
after treatment. Long-term oncological data are warranted to provide ultimate proof for or against focal therapy.
Keywords Prostate cancer · Focal therapy · Irreversible electroporation · Radical prostatectomy · Robotic
Introduction
Until recently no accepted curative prostate cancer (PCa) 
treatment had been compared in a randomized controlled 
trial (RCT) [1, 2]. Eight comparative RCTs were prema-
turely closed due to the lack of physician equipoise or patient 
preference [3]. The ProtecT trial was randomized between 
radical prostatectomy (RP), radiotherapy and active moni-
toring [1]. The trial recruited patients from 1999 to 2009, 
total estimated costs were £35 million [3]. The 10-year 
outcomes showed no differences in PCa-specific mortality 
and the patient-reported outcomes elucidated that RP had 
the greatest negative effect on erections sufficient for inter-
course (ESI) and urinary continence (UC) [1, 4]. However, 
one may argue that the landscape of PCa has drastically 
changed since. The majority (77%) of the included patients 
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harboured Gleason 3 + 3 = 6 on biopsy, who nowadays are 
most likely to have been actively monitored using improved 
surveillance protocols [2]. Moreover, technological advance-
ments and experience improved the preservation of genito-
urinary function following RP [5–7].
Chen et al. published an alternative method to compare 
prospectively acquired patient-reported quality of life (QoL) 
outcomes [8]. These authors compared RP, radiotherapy, 
brachytherapy and active surveillance using propensity 
score-weighted matched cohorts. Baseline characteristics 
were matched, whilst the cohorts had identical follow-up 
schemes and methods. A total of 1141 men (treated from 
2011 to 2013) were enrolled in this analysis, thus providing 
up-to-date comparative information on QoL following differ-
ent PCa treatments. This design may also be used to position 
new PCa treatments to the guidelines.
Focal therapy has been introduced as treatment option 
for patients with unifocal low-, to intermediate-risk PCa 
[9]. Adoption of this new treatment concept has been slow, 
despite increasing experience derived from phase 1–2 trials, 
including more than 3000 patients treated and a maximum 
median follow-up of 61 months [3, 9]. The lack of compara-
tive RCTs has been advocated to be one of the main reasons. 
A specific PCa RCT consensus group proposed that cohort-
embedded RCTs with medium-term outcomes (3–5 years) 
might provide proof for this concept [3].
We propose an alternative approach to compare focal 
therapy with current PCa treatments, by propensity score 
pair-matched analysis of cohorts that followed an identical 
follow-up scheme and evaluation. Consensus statements on 
focal therapy patient criteria and selection methods should 
be used to identify a cohort to match to an accepted PCa 
treatment [10, 11]. International registries may provide large 
cohorts to compare the long-term oncological outcomes.
In this study, we aimed to illustrate the potential of this 
design. Focal therapy was performed using irreversible elec-
troporation (IRE) [12]. IRE patients, that were eligible for 
treatment according to the consensus guidelines [10, 11], 
were propensity-score matched to robot-assisted RP (RARP) 
patients. We evaluated the patient-reported QoL outcomes 
and early oncological control following focal IRE versus 
RARP by prospective collection of patient-reported ques-
tionnaires using identical follow-up schemes.
Materials and methods
Study design and patients
Patients receiving single-ablative unifocal IRE (n = 50) 
following the consensus guidelines (February 2013–July 
2016) were propensity score pair-matched to patients who 
received nerve-sparing RARP (n = 325, April 2013–July 
2016) [10, 11]. Eligibility criteria for both IRE and RARP 
patients included patients with clinical stage T1c–T2b, low-, 
to intermediate-risk PCa (ISUP 1–3), written informed con-
sent for QoL evaluation, minimum of 6 months follow-up 
and completion of all baseline questionnaires and matching 
criteria (Supplementary Fig. 1). Extra eligibility criteria for 
RARP patients were: (1) treatment after the completion of 
the single-surgeons learning curve [5], (2) all procedures 
must be nerve-sparing. Early oncological control and pro-
spectively collected patient-reported QoL outcomes were 
evaluated up to 12 months following treatment.
Study procedures
Irreversible electroporation
Pre-treatment tumour localization and treatment planning 
were performed with transrectal or transperineal biopsies, 
guided by pre-biopsy mpMRI. IRE was performed by a sin-
gle-surgeon (PS), including his initial learning curve and 
was executed following the methods as described by Ting 
et al. [13]. A transurethral indwelling catheter was placed to 
drain the bladder before treatment. The procedure was per-
formed as a day stay procedure. The transurethral indwelling 
catheter was removed within 2–5 days after treatment.
Robot‑assisted radical prostatectomy
RARP was performed by a single-surgeon (PS) after com-
pletion of his initial learning curve (> 3000 prior open RP 
and 1500 RARPs) [5]. The techniques described by Patel 
et al. [14] were followed and the Da-Vinci Xi surgical system 
with 6 access ports was used (Intuitive Surgical  Sunnyvale®, 
CA, USA). Specifically, after the bladder neck and seminal 
vesicles dissection, a combined antegrade/retrograde non-
thermal nerve-sparing procedure was performed. Accessory 
pudendal arteries were preserved. The dorsal venous plexus 
was dissected using electro-cautery and sutured. A suspen-
sory suture to the symphysis pubis was placed after removal 
of the prostate. A two-layer Rocco stitch was used to support 
the posterior bladder anastomosis [15]. An anterior bladder 
reconstruction was performed if needed. Extended lymph 
node dissection was performed in cases with > 5% chance 
of lymph node metastasis according to the Briganti nomo-
gram [16].
Complication, quality of life and early oncological 
control evaluation
Early surgical complications were classified as specified by 
the Clavien–Dindo classification [17]. Patient-reported QoL 
outcomes were acquired at baseline, 1.5, 3, 6, and 12 months 
using the Expanded Prostate Cancer Index Composite 
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(EPIC) [18], AUA symptom score [19], Short Form Health 
Survey (SF-12) with Physical and Mental Component Sum-
mary [20]. Clinical data managers collected the QoL ques-
tionnaires to decrease any potential impact of treating phy-
sicians. Transperineal biopsies were performed 12 months 
following IRE to determine early oncological control. For 
RARP and IRE, serial PSA testing was utilized.
Analysis
Quality of life comparison
Primary analysis was performed on UC and ESI as these 
measures of genito-urinary function are most commonly 
used to report genito-urinary function outcomes following 
PCa treatments [6, 7, 21]. UC was defined as pad-free conti-
nence. ESI was defined as erections sufficient for intercourse 
with or without the use of medication. Rates of UC and ESI 
were compared between IRE and RARP up to 12 months, 
with absolute risk differences and at 12 months the number 
needed to treat (NNT) was calculated to prevent 1 man to 
develop UC or ESI. Secondary analysis included summary 
score differences on the questionnaires over 12 months 
(EPIC urinary, bowel and sexual domain, AUA symptom 
score, and SF-12 Physical and Mental survey). Oncological 
failure rates for IRE were defined by positive follow-up biop-
sies at 12 months with significant PCa (high-volume ISUP 1 
or any 2/3). For RARP, this was defined as biochemical fail-
ure (PSA ≥ 0.2 μg/L) or the need for adjuvant radiotherapy 
within 12 months.
Matching criteria and statistical analysis
Matching was performed on age, pre-treatment PSA, ISUP 
score on biopsy, number of positive cores, baseline question-
naires scores and rates of pad-free UC and ESI. Propensity 
score matching was performed for 1:1 nearest neighbour 
identification. Missing data on follow-up questionnaires 
were not imputed and data with ≥ 1 follow-up time point 
were included in the comparative analysis. We employed 
mixed-effects models to evaluate the effect of treatment 
(IRE and RARP) on QoL. In this model, the outcomes (i.e., 
dependent variables) were EPIC urinary, sexual and bowel 
score, SF-12 physical and mental score, AUA score and rates 
of ESI and pad-free UC. Prior to the analysis, all outcome 
variables were re-scaled to have zero mean and unit variance 
(i.e., z-score). In this model, the standardized outcome for 
each individual i at a time point j, denoted by Yij, is mod-
elled as a linear function of time: Yij = π0j + π1j × timeij + rij, 
in which π0j and π1j represent the estimated baseline and rate 
of change for an individual, and rij is within-subject random 
error, which is assumed to follow a normal distribution with 
men 0 and variance of σ2. In the second level, the collection 
of π0j and π1j was then modelled as a linear function of treat-
ment xj, so that the final model is: Yij = [b00 + b10 × timeij 
+ b01 × Xj + b11 × timeij × Xj] + [u0j + u1j × timeij + rij], where 
the terms u0j and u1j represent between-subject variance in 
the baseline estimates and between-subject variance in the 
rates of change, respectively. The Mann–Whitney U and Chi 
square tests were performed to assess matching characteris-
tics. Data analysis was conducted using R including package 
“lme4” [22, 23].
Results
Patient and matching characteristics
Fifty patients treated with IRE (February 2013–July 2016) 
were matched to the nearest individual RARP neighbour 
(April 2013–July 2016) without significant matching crite-
ria and patient characteristic differences (Table 1). Bilateral 
nerve-sparing RARP was performed in 94% (n = 47/50) of 
the patients. Three patients received unilateral nerve-preser-
vation. All patients completed their baseline questionnaires. 
At 1.5, 3, 6, and 12 months, the response rate was 93, 97, 
94 and 71% of the 100 patients, respectively. In Supplemen-
tary Fig. 1, the flowchart of the inclusion and matching is 
displayed.
Early surgical complications
Early surgical complications for RARP included a total of 
nine Clavien–Dindo 1 complications and five Clavien–Dindo 
2 complications (urinary retention n = 5, urinary tract infec-
tion n = 4, postoperative anemia requiring blood transfusion 
n = 1).
Eleven Clavien–Dindo 1 (mild haematuria, urgency and 
postoperative pain) and seven Clavien–Dindo 2 (urinary 
tract infection and severe postoperative pain related to the 
indwelling catheter) complications were reported for IRE.
Patient‑reported quality of life outcomes
Baseline and absolute changes from baseline for each QoL 
measure, stratified by treatment group, are shown in supple-
mentary Table 1. The results of mixed-effects model analysis 
are shown in Supplementary Table 2. Figure 1 illustrates the 
treatment outcomes on the rates of UC and ESI and Sup-
plementary Fig. 2 the mixed-effect models on the patient-
reported QoL results.
Urinary domain
IRE was superior to RARP in preserving pad-free UC during 
the first 12 months of follow-up (p < 0.01, Supplementary 
 World Journal of Urology
1 3
Table 2). The absolute risk reduction was 44, 21, 13 and 
14% at 1.5, 3, 6, and 12 months, respectively. The num-
ber needed to treat (NNT) to preserve the UC of 1 man at 
12 months was 8.3 IREs. RARP and IRE were associated 
with reduced urinary symptoms following treatment (AUA); 
however, IRE patients initially had more complaints without 
statistically significant difference (Supplementary Tables 1, 
2). For EPIC urinary, there was a significant reduction at 
6 weeks, but the scores then regressed back towards baseline 
levels at 3 months without significant differences between 
RARP and IRE or over the 12-month period (Supplementary 
Tables 1, 2).
Sexual function
IRE was superior to RARP in preserving ESI (p < 0.05, Sup-
plementary Table 2) during the first 12 months of follow-up. 
The absolute risk reduction to develop erectile dysfunction 
was 32, 46, 27 and 22% at 1.5, 3, 6, and 12 months, respec-
tively. The NNT to preserve the ESI of 1 man at 12 months 
was 4.5 IREs. EPIC sexual summary scores were signifi-
cantly reduced for both IRE and RARP, with no differences 
between the two treatments (Supplementary Tables 1, 2).
Remaining questionnaires
No differences were found on the EPIC bowel domain and 
SF-12 Mental survey during the first 12 months of follow-up 
(Supplementary Tables 1, 2). RARP patients showed sig-
nificantly more physical complaints following surgery than 
IRE patients on the SF-12 Physical survey at 6 weeks (Sup-
plementary Table 1); this regressed back to baseline levels 
at 3 months.
Early oncological control
44 (88%) IRE patients underwent follow-up biopsies, five 
refused while one is awaiting biopsies. In total, 70.5% 
(31/44) men were free of significant PCa. Of those with 
residual significant PCa (29.5%, 13/44), five were moni-
tored actively, three underwent salvage IRE, three salvage 
RARP, one salvage low-dose rate brachytherapy. One patient 
was diagnosed with metastatic disease directly after IRE 
due to persisting elevated PSA (> 10 ng/mL) that refused 
pre-treatment template-mapping biopsies and staging imag-
ing. The median decline in PSA after IRE was 51% (IQR 
28–85%) when the median post-IRE nadir PSA (2.8 ng/mL, 
Table 1  Patient and matching 
characteristics (median, IQR)
Patient characteristics are shown in median and interquartile ranges (in brackets) or in frequency. Baseline 
characteristics were statistically compared and a match was defined as non-statistical differences (p > 0.05, 
preferably close to p = 1)
Variable IRE RARP Match (p value)
Age (years) 67 (62–73) 67 (64–71) Yes (p = 0.953)
PSA (μg/L) 5.9 (3.3–7.3) 6.3 (4.3–7.7) Yes (p = 0.229)
Prostate volume (cc) 35 (30–50) 37.5 (27–50)
Clinical stage
 T1c 37 34
 T2a 12 14
 T2b 1 2
Biopsy (ISUP)
 1 8 9
 2 33 31
 3 9 10
 Average ISUP 2 (2–2) 2 (2–2) Yes (p = 0.997)
 # of cores taken 22 (10–29) 19 (14–31)
 # of positive cores 4.0 (2.8–5.3) 4.0 (3.0–7.0) Yes (p = 0.189)
Baseline function
 EPIC urinary 92 (79–98) 91 (83–96) Yes (p = 0.920)
 EPIC sexual 65 (48–81) 69 (41–79) Yes (p = 0.820)
 EPIC bowel 96 (93–100) 96 (93–98) Yes (p = 0.756)
 SF-12 physical 56 (52–57) 55 (52–58) Yes (p = 0.588)
 SF-12 mental 57 (50–58) 56 (51–59) Yes (p = 0.807)
 AUA 6 (3–13) 7 (3–11) Yes (p = 0.978)
 Erections sufficient for intercourse 69% (34/49) 68% (34/50) Yes (p = 0.882)
 Pad-free continence rate 98% (49/50) 98% (49/50) Yes (p = 1.000)
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IQR 0.9–4.5) was compared with the median pre-IRE PSA 
(5.9 ng/mL, IQR 3.3–7.3). None of the RARP patients expe-
rienced biochemical failure (PSA ≥ 0.2 ng/mL) within the 
first 12 months of follow-up.
Discussion
Our results demonstrated superior rates of preserved UC 
and ESI with IRE compared to expert RARP in unifocal 
localized PCa. IRE was compared to high-standard RARP, 
included the first cases treated with IRE and it may be 
less complicated, time consuming and more economical 
to perform IRE. Our 12-month results are limited by large 
proportions of missing data, 29% versus 3–7% on other 
time points. Moreover, improvement of ESI and UC fol-
lowing RARP has been described up to 24–36 months 
[24]. Therefore, the 12-month follow-up of this study may 
underestimate the final rates of ESI and UC for both RARP 
and IRE patients. The outcomes of this study also showed 
that focal therapy is not without morbidity (e.g., 28% of 
potent men developed erectile dysfunction), especially in 
older men with poor baseline functioning. Short-term uri-
nary complaints were more pronounced in IRE patients 
and were most likely due to irritation to the bladder by the 
extended electrical field [25]. Some of the summary scores 
did not reflect the different effects within their domain. For 
example, the EPIC urinary summary scores were not sta-
tistically different despite significant outcome differences 
between RARP and IRE on UC.
Patients were matched on specific parameters for QoL 
outcomes (e.g., baseline QoL scores), since these factors 
are shown to have a pronounced effect on the rates of ESI 
or UC following RARP [6, 7]. Interestingly, baseline gen-
ito-urinary function was not included in the randomization 
stratification of the ProtecT trial [4]. In the past years, the 
rates of UC and ESI following RARP improved remark-
ably compared to the RP outcomes in the ProtecT trial 
(12-month pad-free UC and ESI rates were 74 and 25%, 
respectively) [4, 6, 7, 21]. Our RARP rates of pad-free 
UC and ESI at 12 months (median age of 67 years) are 
concordant with the literature and superior to the results 
of our RARP learning curve analysis and the ProtecT trial 
[5–7].
Fig. 1  a, b Rates of pad-free urinary continence (no need for urinary 
pads per 24 h), for all men (a) and men who were continent at base-
line (b). c, d Rates of erections sufficient for intercourse (erections 
firm enough to have intercourse), for all men (c) and men who were 
potent at baseline (d)
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The intent of focal therapy is to minimize collateral 
damage to adjacent anatomical structures by tissue-selec-
tive treatment [9]. Therefore, the genito-urinary and QoL 
outcomes of focal IRE must outweigh the results following 
RARP; as per definition, the oncological control will be infe-
rior. In order to evaluate this equilibrium, long-term onco-
logical data must become available. This study is limited by 
the absence of long-term oncological data (e.g., metasta-
sis-free survival, overall and PCa-specific mortality). IRE 
patients were more likely to experience early oncological 
failure compared to RARP patients when using surrogates of 
short-term oncological control. However, it is important to 
highlight that this analysis included all IRE patients during 
the initial learning curve. Our institutional analysis showed 
that, when adhering to the consensus guidelines on patient 
selection methods, and when the IRE procedure was opti-
mized, the oncological failure rate decreased to 13% [26, 
27]. This trade-off of an increase chance for residual PCa 
versus improved preservation of urinary and erectile func-
tion needs to be discussed during informed consent. The 
potential presence of residual disease following IRE may 
cause psychological burden for patients. However, this 
seems not to apply to our cohort, as neither treatment illus-
trated worsening on the SF-12 mental survey. Other limi-
tations include the retrospective analysis of prospectively 
acquired data, single-surgeon procedures and small cohort 
size.
However, the intent of this study was not to argue for a 
change in practice based on our short-term improved rates 
of UC and ESI versus the impaired surrogates of oncologi-
cal control following IRE. We aimed to address the need 
for a new trial design to compare curative PCa treatments, 
show the feasibility of this propensity-score matching design 
and validate the rationale of focal therapy. The highest level 
of unbiased data is attained by the use of head-to-head 
multi-centre randomized trials, including large cohorts and 
long-term follow-up. In comparison, propensity score pair-
matched cohorts are inherently more prone to be biased. 
Nevertheless, one may argue that the ever-evolving PCa 
therapy landscape, biological nature of the disease and 
strong patient preference hinder the ability to draw firm 
conclusions from long-term randomized trials. Carefully 
matched cohorts with long-term QoL and oncological out-
come data derived from international registries have the 
potential to approximate the strength of randomized trials. 
To reach this goal, it will be crucial to establish the use of 
identical follow-up methods, time points and questionnaires 
throughout different treatments. This may create an open 
platform that may compare new PCa treatments affordably 
and efficiently to the current accepted segments.
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